



SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

■ L1
Identity

■ L2
Purity

■ L3
Net Peptide Content

■ L4
Sterility

■ L8
Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A - right

Brand	Latitude 40 Aminos	Product	Retatrutide
Lot / Batch	RVA-RT-610A01	Label Claim	10 mg
Matrix	Lyophilized powder	Sample Count	1
Vial Size	3mL	Cap Color	Clear
Crimp Color	Bronze	Contents Color	White
Seal Intact	Yes	Condition	sealed, intact
Received	Oct 1, 2026 PT	Sampling	client submitted



Test Results

Test	Specification	Result	
Identity research screen	every vial within ± 1 Da of 4731.421 Da	4731.39 Da	PASS
Purity research screen	≥ 99.25 area %	99.97%	PASS
Net Peptide Content research screen	every vial within $\pm 10\%$ of 10 mg	Vial A: 10.38 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS



Layer Results

1 Identity

LC-MS (ESI+)

4731.39 Da

every vial within ± 1 Da of 4731.421 Da

PASS

Theoretical mass

4731.421 Da

Acceptance

within ± 1 Da

Vial A

4731.39 Da · PASS

4731.39 Da PASS

2 Purity

RP-HPLC 214nm (USP <621>)

99.97%

≥ 99.25 area %

PASS

Acceptance

$\geq 99.25\%$

Vial A

99.97% · PASS

Criterion
source

**Axiom Analytics SPEC-PURITY-001, Revision 1, effective
2026-08-31**

99.97% PASS

limit 99.25%

3 Net Peptide Content

Quantitative HPLC vs reference std

Vial A: 10.38 mg

every vial within $\pm 10\%$ of 10 mg

PASS

Target

10 mg ($\pm 10\%$)

Vial A

10.38 mg · PASS

Confirmed container volume

Unknown

Content concentration

Unknown

10.38 mg PASS

4 Sterility · Rapid PCR

Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected

Rapid PCR screen

PASS

Result

Target DNA not detected

Acceptance

Rapid PCR screen

Target
panel

**Pan-bacterial 16S rRNA gene (VIC), Pan-fungal 18S rRNA
gene (FAM)**

Run controls valid.



8

Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected

no fentanyl or analog at or above 1 ng/mg

PASS

Result	Not detected	Detection limit	1 ng/mg
Analytes screened	Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)	Source container	A

Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	Alana Reeves	Analyst Signature	ed25519:9a65e8f4118c7fbf9bce04bc...
Technical Reviewer	Michael Niles	Reviewer Signature	ed25519:425ce5fffe38ce44fc335b70...
Laboratory Director	Daniel Brennan	Director Signature	ed25519:c0b57466cd0f838639fbb74b...

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-1572-2WXG>.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: 2712d89827e0ce11136a78661c486c8bb636d92a508971f77b915f064f49aa9c...

Seal: ed25519:b40c930b69db80462c344278bfd07b7a9f6fcdaa...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.

ILS Laboratories

8222 Vickers St, Suite 106, San Diego, CA 92111
(619) 329-3999 | ils-lab.com

Retatrutide - 10mg

Tested for: Latitude 40 Aminos

www.lat40aminos.com

COA #: COA-2026-CVBEL9

Lot Number: Lot: RT10-1

Labeled Content: 10mg

Volume: 3mL

Analysis Date: 07/28/2026

Appearance: Good

Volume: 3mL

Date Received: 07/13/2026

Method: Purity, Identity & Quantitation (HPLC)

PASS



Scan to verify
authenticity at ils-lab.com
Access Code: QXTYNBDQ

Identity	Peptide Purity	Fentanyl Free
Retatrutide	99.36%	


Purity, Identity & Quantitation (HPLC)

Analyte	Specification	Result	Unit	Status
Peptide Purity (HPLC)	>= 95.0%	99.36%	%	PASS
Net Peptide Content	Report Only	10.53	mg	N/A
Identity (HPLC-RTM)	Retatrutide	Confirmed	-	PASS
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	Not Detected	-	PASS



Retatrutide 10mg - Lot: RT10-1

HPLC Chromatogram



Retatrutide 10mg - Lot: RT10-1: UV Chromatogram

Notes & Methodology

- Date Tested: 07/28/2026. Methods: Purity, Identity & Quantitation (HPLC).
- The sample was confirmed to be Retatrutide by HPLC. Identification by chromatographic retention time comparison with a reference standard.
- Peptide purity determined by RP-HPLC area normalization at 214 nm. Value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.



Handwritten signature

Dr. Greg Kalyuzhny
Lab Director
7/28/2026

COA #: COA-2026-CVBEL9
Access Code: QXTYNBDQ
Verify: portal.ils-lab.com
Issued: 7/28/2026



Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-2534-GN3T
Retatrutide · Lot RVA-RT-610A16
Issued Oct 20, 2026 PT · v1
Verify: 32C9-4DB0-318D



SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

L1
Identity

L2
Purity

L3
Net Peptide Content

L4
Sterility

L8
Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A - right

Brand	Latitude 40 Aminos	Product	Retatrutide
Lot / Batch	RVA-RT-610A16	Label Claim	20 mg
Matrix	Lyophilized powder	Sample Count	1
Vial Size	3mL	Cap Color	Translucent Pink
Crimp Color	Silver / Aluminum	Contents Color	White
Seal Intact	Yes	Condition	sealed, intact
Received	Oct 1, 2026 PT	Sampling	client submitted



Test Results

Test	Specification	Result	
Identity research screen	every vial within ± 1 Da of 4731.421 Da	4731.305 Da	PASS
Purity research screen	≥ 99.25 area %	99.65%	PASS
Net Peptide Content research screen	every vial within $\pm 10\%$ of 20 mg	Vial A: 20.6 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS



Layer Results

1 Identity LC-MS (ESI+)

4731.305 Da
every vial within ± 1 Da of 4731.421 Da **PASS**

Theoretical mass **4731.421 Da** Acceptance **within ± 1 Da**
Vial A **4731.305 Da · PASS**

4731.305 Da PASS

2 Purity RP-HPLC 214nm (USP <621>)

99.65%
 ≥ 99.25 area % **PASS**

Acceptance **$\geq 99.25\%$** Vial A **99.65% · PASS**
Criterion **Axiom Analytics SPEC-PURITY-001, Revision 1, effective**
source **2026-08-31**

99.65% PASS

limit 99.25%

3 Net Peptide Content Quantitative HPLC vs reference std

Vial A: 20.6 mg
every vial within $\pm 10\%$ of 20 mg **PASS**

Target **20 mg ($\pm 10\%$)** Vial A **20.6 mg · PASS**
Confirmed container volume **Unknown** Content concentration **Unknown**

20.6 mg PASS

4 Sterility · Rapid PCR Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected
Rapid PCR screen **PASS**

Result **Target DNA not detected** Acceptance **Rapid PCR screen**
Target **Pan-bacterial 16S rRNA gene (VIC), Pan-fungal 18S rRNA**
panel **gene (FAM)**

Run controls valid.



8

Fentanyl Screen

LC-MS/MS targeted adulterant screen


none detected

no fentanyl or analog at or above 1 ng/mg

PASS

Result	Not detected	Detection limit	1 ng/mg
Analytes screened	Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)	Source container	A

LC-MS Mass Spectrum · Vial A · LC-MS (ESI+)




Recorded deconvoluted average mass: 4731.305 Da

Charge Observed m/z Deconvoluted mass (Da) Relative intensity (%)


4+	1183.833	4731.302	56.3
5+	947.267	4731.298	100.0
6+	789.560	4731.315	56.3
7+	676.906	4731.292	10.0
8+	592.422	4731.318	0.6



SCAN TO VERIFY

HPLC Chromatogram · Vial A · RP-HPLC 214 nm


Peak	Retention time (min)	Area %
1	6.562	0.071
2	7.043	0.088
3	7.468	99.650
4	8.283	0.150
5	8.572	0.041


Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.



Digital Signatures

Analyst	Alana Reeves	Analyst Signature	ed25519:e4a005f7a73f9c60d718e57e...
Technical Reviewer	Michael Niles	Reviewer Signature	ed25519:a9eec8eb601d07bad78732ba...
Laboratory Director	Daniel Brennan	Director Signature	ed25519:e88a490bc348be238abcc184...

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-2534-GN3T>.


✓ **CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)**

SHA-384: 75d0c0e13bd381378dfa9b14b4ac5ade19da0816e431a040f02cd9ed7c60106...

Seal: ed25519:650a17a0446e2cb95366def076f32f8cc8d19d46...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.



ILS Laboratories

8222 Vickers St, Suite 106, San Diego, CA 92111
(619) 329-3999 | ils-lab.com

Retatrutide - 20mg

Tested for: Latitude 40 Aminos

www.lat40aminos.com

COA #: COA-2026-79RZN2

Lot Number: Lot: RT20-1

Labeled Content: 20mg

Volume: 3mL

Analysis Date: 07/28/2026

Appearance: Good

Volume: 3mL

Date Received: 07/13/2026

Method: Purity, Identity & Quantitation (HPLC)

PASS



Scan to verify
authenticity at ils-lab.com
Access Code: 25894WJV

Identity	Peptide Purity	
Retatrutide	99.81%	 Fentanyl Free


Purity, Identity & Quantitation (HPLC)

Analyte	Specification	Result	Unit	Status
Peptide Purity (HPLC)	>= 95.0%	99.81%	%	PASS
Net Peptide Content	Report Only	21.09	mg	N/A
Identity (HPLC-RTM)	Retatrutide	Confirmed	-	PASS
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	Not Detected	-	PASS



Retatrutide 20mg - Lot: RT20-1

HPLC Chromatogram



Retatrutide 20mg - Lot: RT20-1: UV Chromatogram

Notes & Methodology

- Date Tested: 07/28/2026. Methods: Purity, Identity & Quantitation (HPLC).
- The sample was confirmed to be Retatrutide by HPLC. Identification by chromatographic retention time comparison with a reference standard.
- Peptide purity determined by RP-HPLC area normalization at 214 nm. Value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.



Handwritten signature

Dr. Greg Kalyuzhny
Lab Director
7/28/2026

COA #: COA-2026-79RZN2
Access Code: 25894WJV
Verify: portal.ils-lab.com
Issued: 7/28/2026



SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

■ L1
Identity

■ L2
Purity

■ L3
Net Peptide Content

■ L4
Sterility

■ L8
Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A - right

Brand	Latitude 40 Aminos	Product	Retatrutide
Lot / Batch	RVA-RT-610A18	Label Claim	30 mg
Matrix	Lyophilized powder	Sample Count	1
Vial Size	3mL	Cap Color	Clear
Crimp Color	Silver / Aluminum	Contents Color	White
Seal Intact	Yes	Condition	sealed, intact
Received	Oct 1, 2026 PT	Sampling	client submitted



Test Results

Test	Specification	Result	
Identity research screen	every vial within ± 1 Da of 4731.421 Da	4731.447 Da	PASS
Purity research screen	≥ 99.25 area %	99.98%	PASS
Net Peptide Content research screen	every vial within $\pm 10\%$ of 30 mg	Vial A: 31.08 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS



Layer Results

1 Identity

LC-MS (ESI+)

4731.447 Da

every vial within ± 1 Da of 4731.421 Da

PASS

Theoretical mass

4731.421 Da

Acceptance

within ± 1 Da

Vial A

4731.447 Da · PASS

4731.447 Da PASS

2 Purity

RP-HPLC 214nm (USP <621>)

99.98%

≥ 99.25 area %

PASS

Acceptance

$\geq 99.25\%$

Vial A

99.98% · PASS

Criterion
source

**Axiom Analytics SPEC-PURITY-001, Revision 1, effective
2026-08-31**

99.98% PASS

limit 99.25%

3 Net Peptide Content

Quantitative HPLC vs reference std

Vial A: 31.08 mg

every vial within $\pm 10\%$ of 30 mg

PASS

Target

30 mg ($\pm 10\%$)

Vial A

31.08 mg · PASS

Confirmed container volume

Unknown

Content concentration

Unknown

31.08 mg PASS

4 Sterility · Rapid PCR

Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected

Rapid PCR screen

PASS

Result

Target DNA not detected

Acceptance

Rapid PCR screen

Target
panel

**Pan-bacterial 16S rRNA gene (VIC), Pan-fungal 18S rRNA
gene (FAM)**

Run controls valid.



8

Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected

no fentanyl or analog at or above 1 ng/mg

PASS

Result	Not detected	Detection limit	1 ng/mg
Analytes screened	Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)	Source container	A

Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	Alana Reeves	Analyst Signature	ed25519:b0ed4595fe809ceea21fef4e...
Technical Reviewer	Michael Niles	Reviewer Signature	ed25519:ec04493c25c0c187406a788e...
Laboratory Director	Daniel Brennan	Director Signature	ed25519:635a879b38854ddf5f11ed30...

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-4248-JFSB>.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: 97e35feb1674f5094863038b596cea21af788866708a768961da08172000edd8...

Seal: ed25519:ee0a22a96ad4c05250d008087fe6bdf62a7b5e16...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.